May 17, 2023 / 06:35PM GMT
Rahul Sood - RBC Capital Markets - Analyst
Welcome to the 2023 RBC Global Healthcare Conference. I'm Rahul Sood, managing director in the healthcare investment banking group. And I'm joined on the stage today by Joe Todisco, the CEO of CorMedix. Joe, thanks for joining.
Joe Todisco - CorMedix Inc. - CEO
Thank you.
Questions and Answers:
Rahul Sood - RBC Capital Markets - AnalystOkay. So for those of us who aren't familiar with the CorMedix story, can you please provide us with a brief intro of the company and the lead asset, DefenCath, specifically, how DefenCath differentiated from the current products and procedures in place to protect against catheter-related bloodstream infections?
Joe Todisco - CorMedix Inc. - CEO
All right. Sure. Thanks. Well, thanks, those of you that are in here, for joining.
So CorMedix is a pre-commercial stage biotech company. And our lead product, DefenCath, the NDA was just resubmitted to FDA this past Monday. So the product